MGNX - MacroGenics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
27.87
-0.93 (-3.23%)
As of 9:53AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close28.80
Open28.47
Bid27.84 x 1800
Ask28.14 x 1200
Day's range28.24 - 28.47
52-week range4.04 - 32.18
Volume24,113
Avg. volume3,272,234
Market cap1.369B
Beta (5Y monthly)2.82
PE ratio (TTM)N/A
EPS (TTM)-3.10
Earnings date29 Jul 2020 - 03 Aug 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est29.36
  • Here's Why MacroGenics Jumped 156.6% in the First Half of 2020
    Motley Fool

    Here's Why MacroGenics Jumped 156.6% in the First Half of 2020

    Investors remain optimistic that the leading drug candidate can earn marketing approval before the end of the year.

  • GlobeNewswire

    MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting

    Rockville, MD, June 22, 2020 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.

  • GlobeNewswire

    MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Stephen Eck, M.D., Ph.D. as Senior Vice President, Clinical Development & Chief Medical Officer, effective beginning July 1, 2020. “Stephen will be a tremendous asset to our company.”

  • GlobeNewswire

    MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to margetuximab, an investigational, Fc-engineered monoclonal antibody targeting HER2 for the treatment of gastric and gastroesophageal junction cancer. Margetuximab is currently being evaluated in the Phase 2/3 MAHOGANY clinical trial in combination with checkpoint inhibition, with or without chemotherapy, as a potential first-line treatment for patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.

  • GlobeNewswire

    MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced research published in the journal Science Translational Medicine that describes a gene expression signature of the tumor microenvironment in patients with acute myeloid leukemia (AML) that is associated with resistance to chemotherapy and response to flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule currently in clinical development for the treatment of primary induction failure and early relapsed AML. The research was led by Sergio Rutella, M.D., Ph.D., FRCPath, Professor of Cancer Immunotherapy, John van Geest Cancer Research Centre at Nottingham Trent University in the UK.

  • Here's Why MacroGenics Is Tumbling 17.3% Today
    Motley Fool

    Here's Why MacroGenics Is Tumbling 17.3% Today

    MacroGenics (NASDAQ: MGNX) shares are falling 17.3% as of 12:15 p.m. EST on Friday. The drop coincides with the release of the company's presentations at the annual American Society of Clinical Oncology meeting, and it follows a surge in its share price earlier this month. The ASCO conference is highly anticipated, and historically, investors have bought shares in stocks presenting at the conference ahead of time, hoping for a short-term pop.

  • GlobeNewswire

    MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that during the recent mid-cycle communication with the U.S. Food and Drug Administration (FDA), the FDA notified the Company that it is no longer planning to hold an Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the Biologics License Application (BLA) for margetuximab. The FDA also stated it continues to anticipate meeting the Prescription Drug User Fee Act (PDUFA) goal date for the application review, which is December 18, 2020.

  • GlobeNewswire

    MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced plans for a clinical study intended to support registration in the U.S. of flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule for patients with acute myeloid leukemia (AML) who are refractory to induction therapy. Informed by recent discussions with the U.S. Food and Drug Administration (FDA), the Company plans a single-arm, registration-enabling clinical study to evaluate flotetuzumab in up to 200 patients with primary induction failure (PIF) or early relapse (ER) AML.

  • GlobeNewswire

    MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a conference call and audio webcast on Friday, May 29 at 4:30 p.m. ET. MacroGenics management will be joined by external guest presenters to review the preliminary clinical results from the ongoing Phase 1 studies of MGD013 and MGC018 that are part of the American Society of Clinical Oncology (ASCO) ASCO20 Virtual Scientific Program. To participate in the MacroGenics ASCO 2020 Conference Call, please dial (833) 651-1036 (domestic) or (918) 922-6233 (international) ten minutes prior to the start of the call and provide the Conference ID: 7765546.

  • GlobeNewswire

    MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary results from two of its investigational pipeline molecules. Data covering safety and preliminary anti-tumor activity from the Phase 1 dose escalation and expansion clinical trial of MGD013, a bispecific, tetravalent DART® molecule binding PD-1 and LAG-3, and the Phase 1 dose expansion study of MGC018, an antibody-drug conjugate (ADC) targeting B7-H3, will be presented at the American Society of Clinical Oncology (ASCO) upcoming ASCO20 Virtual Scientific Program to be held May 29-31, 2020.

  • Are Options Traders Betting on a Big Move in MacroGenics (MGNX) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in MacroGenics (MGNX) Stock?

    Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.

  • Why MacroGenics Stock Jumped 29% Today
    Motley Fool

    Why MacroGenics Stock Jumped 29% Today

    Optimism is growing ahead of the release of abstracts this week for the upcoming ASCO 2020 conference.

  • 3 Small-Cap Biotech Stocks That Surged Last Week
    Motley Fool

    3 Small-Cap Biotech Stocks That Surged Last Week

    Last week, shares of these three biotech stocks rocketed higher, but their market values are still relatively small. Here's what you need to know about the businesses behind these recent stock market run-ups before thinking about adding them to a portfolio you'd like to manage successfully.

  • Macrogenics Inc (MGNX) Q1 2020 Earnings Call Transcript
    Motley Fool

    Macrogenics Inc (MGNX) Q1 2020 Earnings Call Transcript

    MGNX earnings call for the period ending March 31, 2020.

  • Here's Why MacroGenics Stock Is Skyrocketing 171% Today
    Motley Fool

    Here's Why MacroGenics Stock Is Skyrocketing 171% Today

    After MacroGenics (NASDAQ: MGNX) updated investors on its clinical-stage drug pipeline and current financial position, its shares are soaring 171% as of 12:45 am EDT Wednesday. After the market's closing bell on Tuesday, the biotech company's management said it remains on track to report final overall survival (OS) data for the phase 3 SOPHIA study of margetuximab in HER2-positive metastatic breast cancer this year. If the data is solid, MacroGenics believes it could get a Food and Drug Administration decision as soon as December 2020.

  • MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates

    MacroGenics (MGNX) delivered earnings and revenue surprises of 9.90% and 84.12%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results

    ROCKVILLE, Md., May 05, 2020 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.

  • Trump Pushes for US-Made Medical Products: 4 Winners
    Zacks

    Trump Pushes for US-Made Medical Products: 4 Winners

    An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.

  • GlobeNewswire

    MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting

    Rockville, MD, April 29, 2020 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.

  • GlobeNewswire

    MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) will now be held by means of a virtual format only due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and related recommendations and orders from federal and state governmental authorities. The date and time of the meeting, May 14, 2020 at 9:00 a.m. ET, as disclosed in MacroGenics’ proxy statement for the meeting, has not changed. Stockholders will not be able to attend the 2020 Annual Meeting in person.

  • GlobeNewswire

    MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter 2020 after the market closes on Tuesday, May 5, 2020. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, May 5, 2020 at 4:30 p.m. ET. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm.

  • GlobeNewswire

    MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced data related to flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule being evaluated in patients with refractory acute myeloid leukemia (AML). The data will be presented during a plenary session at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 27-28, 2020.

  • GlobeNewswire

    MacroGenics Announces Departure of Chief Medical Officer

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that Jon Wigginton, M.D., Senior Vice President, Clinical Development & Chief Medical Officer, will be leaving the Company effective March 27, 2020 to pursue a new opportunity.

  • GlobeNewswire

    MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, Feb. 27, 2020 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.

  • Associated Press

    MacroGenics: 4Q Earnings Snapshot

    ROCKVILLE, Md. (AP) _ MacroGenics Inc. (MGNX) on Tuesday reported a loss of $30.4 million in its fourth quarter. On a per-share basis, the Rockville, Maryland-based company said it had a loss of 62 cents. The results topped Wall Street expectations.